These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 20733504)

  • 1. Vascular endothelial growth factor receptor 2-specific microbubbles for molecular ultrasound detection of prostate cancer in a rat model.
    Fischer T; Thomas A; Tardy I; Schneider M; Hünigen H; Custodis P; Beyersdorff D; Plendl J; Schnorr J; Diekmann F; Gemeinhardt O
    Invest Radiol; 2010 Oct; 45(10):675-84. PubMed ID: 20733504
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ultrasound molecular imaging of VEGFR2 in a rat prostate tumor model using BR55.
    Tardy I; Pochon S; Theraulaz M; Emmel P; Passantino L; Tranquart F; Schneider M
    Invest Radiol; 2010 Oct; 45(10):573-8. PubMed ID: 20808233
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BR55: a lipopeptide-based VEGFR2-targeted ultrasound contrast agent for molecular imaging of angiogenesis.
    Pochon S; Tardy I; Bussat P; Bettinger T; Brochot J; von Wronski M; Passantino L; Schneider M
    Invest Radiol; 2010 Feb; 45(2):89-95. PubMed ID: 20027118
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of low-frequency ultrasound and microbubbles on angiogenesis-associated proteins in subcutaneous tumors of nude mice.
    Shen ZY; Shen E; Zhang JZ; Bai WK; Wang Y; Yang SL; Nan SL; Lin YD; Li Y; Hu B
    Oncol Rep; 2013 Aug; 30(2):842-50. PubMed ID: 23707983
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quantitative ultrasound molecular imaging by modeling the binding kinetics of targeted contrast agent.
    Turco S; Tardy I; Frinking P; Wijkstra H; Mischi M
    Phys Med Biol; 2017 Mar; 62(6):2449-2464. PubMed ID: 28240217
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of acoustic radiation force on the binding efficiency of BR55, a VEGFR2-specific ultrasound contrast agent.
    Frinking PJ; Tardy I; Théraulaz M; Arditi M; Powers J; Pochon S; Tranquart F
    Ultrasound Med Biol; 2012 Aug; 38(8):1460-9. PubMed ID: 22579540
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ultrasound molecular imaging contrast agent binding to both E- and P-selectin in different species.
    Bettinger T; Bussat P; Tardy I; Pochon S; Hyvelin JM; Emmel P; Henrioud S; Biolluz N; Willmann JK; Schneider M; Tranquart F
    Invest Radiol; 2012 Sep; 47(9):516-23. PubMed ID: 22814589
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeted contrast-enhanced ultrasound imaging of angiogenesis in an orthotopic mouse tumor model of renal carcinoma.
    Wei S; Fu N; Sun Y; Yang Z; Lei L; Huang P; Yang B
    Ultrasound Med Biol; 2014 Jun; 40(6):1250-9. PubMed ID: 24613557
    [TBL] [Abstract][Full Text] [Related]  

  • 9. US imaging of tumor angiogenesis with microbubbles targeted to vascular endothelial growth factor receptor type 2 in mice.
    Willmann JK; Paulmurugan R; Chen K; Gheysens O; Rodriguez-Porcel M; Lutz AM; Chen IY; Chen X; Gambhir SS
    Radiology; 2008 Feb; 246(2):508-18. PubMed ID: 18180339
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular targeted enhanced ultrasound imaging of flk1 reveals diagnosis and prognosis potential in a genetically engineered mouse prostate cancer model.
    Xuan JW; Bygrave M; Valiyeva F; Moussa M; Izawa JI; Bauman GS; Klibanov A; Wang F; Greenberg NM; Fenster A
    Mol Imaging; 2009; 8(4):209-20. PubMed ID: 19728975
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differentiation of prostate cancer from normal prostate tissue in an animal model: conventional MRI and dynamic contrast-enhanced MRI.
    Gemeinhardt O; Lüdemann L; Prochnow D; Abramjuk C; Taupitz M; Hamm B; Beyersdorff D
    Rofo; 2005 Jul; 177(7):935-9. PubMed ID: 15973594
    [TBL] [Abstract][Full Text] [Related]  

  • 12. First-in-Human Ultrasound Molecular Imaging With a VEGFR2-Specific Ultrasound Molecular Contrast Agent (BR55) in Prostate Cancer: A Safety and Feasibility Pilot Study.
    Smeenge M; Tranquart F; Mannaerts CK; de Reijke TM; van de Vijver MJ; Laguna MP; Pochon S; de la Rosette JJMCH; Wijkstra H
    Invest Radiol; 2017 Jul; 52(7):419-427. PubMed ID: 28257340
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vivo targeted contrast enhanced micro-ultrasound to measure intratumor perfusion and vascular endothelial growth factor receptor 2 expression in a mouse orthotopic bladder cancer model.
    Chan ES; Patel AR; Larchian WA; Heston WD
    J Urol; 2011 Jun; 185(6):2359-65. PubMed ID: 21511281
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influence of ultrasound induced cavitation on magnetic resonance imaging contrast in the rat liver in the presence of macromolecular contrast agent.
    Frulio N; Trillaud H; Deckers R; Lepreux S; Moonen C; Quesson B
    Invest Radiol; 2010 May; 45(5):282-7. PubMed ID: 20375844
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ultrasound Molecular Imaging With BR55, a Predictive Tool of Antiangiogenic Treatment Efficacy in a Chemo-Induced Mammary Tumor Model.
    Helbert A; Von Wronski M; Colevret D; Botteron C; Padilla F; Bettinger T; Tardy I; Hyvelin JM
    Invest Radiol; 2020 Oct; 55(10):657-665. PubMed ID: 32229739
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dual-Targeted Microbubbles Specific to Integrin αVβ3 and Vascular Endothelial Growth Factor Receptor 2 for Ultrasonography Evaluation of Tumor Angiogenesis.
    Yuan HX; Wang WP; Wen JX; Lin LW; Exner AA; Guan PS; Chen XJ
    Ultrasound Med Biol; 2018 Jul; 44(7):1460-1467. PubMed ID: 29706409
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vivo quantification of ultrasound targeted microbubbles to enhance cancer assessment.
    Sciallero C; Daglio E; Trucco A
    Contrast Media Mol Imaging; 2016 Jul; 11(4):313-8. PubMed ID: 27157493
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of a novel castration-resistant orthotopic prostate cancer model in New Zealand White rabbit.
    Wang Y; Abenojar EC; Wang J; de Leon AC; Tavri S; Wang X; Gopalakrishnan R; Walker E; MacLennan GT; Giles A; Czarnota GJ; Basilion JP; Exner AA
    Prostate; 2022 May; 82(6):695-705. PubMed ID: 35167141
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relationship between retention of a vascular endothelial growth factor receptor 2 (VEGFR2)-targeted ultrasonographic contrast agent and the level of VEGFR2 expression in an in vivo breast cancer model.
    Lee DJ; Lyshchik A; Huamani J; Hallahan DE; Fleischer AC
    J Ultrasound Med; 2008 Jun; 27(6):855-66. PubMed ID: 18499845
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Liver dysplasia: US molecular imaging with targeted contrast agent enables early assessment.
    Grouls C; Hatting M; Rix A; Pochon S; Lederle W; Tardy I; Kuhl CK; Trautwein C; Kiessling F; Palmowski M
    Radiology; 2013 May; 267(2):487-95. PubMed ID: 23360735
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.